China-based Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop twelve early-stage cancer medicine programmes.

• Programme portfolio: The collaboration covers twelve oncology programmes, including antibody-drug conjugates (ADCs) and multi-specific antibodies.
• Development structure: Innovent will contribute eight company-originated early-stage programmes, while Pfizer will contribute four discovery programmes.
• Collaboration scope: The companies will co-develop and share costs for selected programmes as they progress through clinical development.

This summary is based on a news article published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.